CA
CRVS icon

CHI Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

CHI Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200,000
Closed -$458K – 29
2023
Q2 		$458K Sell
200,000
-2,139,402
-91% -$4.44M 0.14% 24
2023
Q1 		$2.13M Sell
2,339,402
-45,000
-2% -$35.1K 0.57% 20
2022
Q4 		$2.03M Hold
2,384,402
– – 0.54% 18
2022
Q3 		$1.95M Buy
2,384,402
+170,218
+8% +$162K 0.52% 22
2022
Q2 		$2.19M Buy
2,214,184
+511,047
+30% +$627K 0.84% 21
2022
Q1 		$2.79M Buy
1,703,137
+1,303,137
+326% +$2.39M 1.19% 19
2021
Q4 		$964K Buy
400,000
+234,073
+141% +$908K 0.32% 20
2021
Q3 		$803K Sell
165,927
-553,205
-77% -$1.64M 0.23% 15
2021
Q2 		$1.92M Buy
719,132
+40,000
+6% +$110K 0.45% 15
2021
Q1 		$2.09M Buy
679,132
+188,255
+38% +$680K 0.42% 14
2020
Q4 		$1.75M Sell
490,877
-92,355
-16% -$372K 0.49% 13
2020
Q3 		$2.34M Buy
583,232
+219,100
+60% +$875K 0.83% 12
2020
Q2 		$990K Hold
364,132
– – 0.39% 15
2020
Q1 		$768K Sell
364,132
-6,175
-2% -$25.1K 1.81% 9
2019
Q4 		$2.01M Sell
370,307
-20,000
-5% -$70K 1.52% 6
2019
Q3 		$1.18M Buy
+390,307
New +$1.64M 1.14% 7

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TL
TowerView LLC New York $155M AUM 30.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CHI Advisors's CRVS Position: Q3 2023 in Review

CHI Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q3 2023, closing a stake of 200,000 shares — an estimated $458K sold.

CHI Advisors first reported a position in CRVS in Q3 2019 and held it in 16 quarters. The position peaked at $2.79M in Q1 2022. 52 funds tracked by Wall St. Rank hold CRVS as of Q3 2023.

  • CHI Advisors reported no remaining Corvus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • CHI Advisors sold 200,000 Corvus Pharmaceuticals shares in Q3 2023, an estimated $458K.
  • CHI Advisors first reported a position in Corvus Pharmaceuticals in Q3 2019 and held it in 16 quarters.
  • CHI Advisors's Corvus Pharmaceuticals position peaked at $2.79M in Q1 2022.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.